ATE409028T1 - Arzneien zur behandlung von nervenerkrankungen - Google Patents

Arzneien zur behandlung von nervenerkrankungen

Info

Publication number
ATE409028T1
ATE409028T1 AT01946787T AT01946787T ATE409028T1 AT E409028 T1 ATE409028 T1 AT E409028T1 AT 01946787 T AT01946787 T AT 01946787T AT 01946787 T AT01946787 T AT 01946787T AT E409028 T1 ATE409028 T1 AT E409028T1
Authority
AT
Austria
Prior art keywords
growth factor
nerve growth
factor production
enhancing
salt
Prior art date
Application number
AT01946787T
Other languages
English (en)
Inventor
Hiromu Ohnogi
Masahiro Shiraga
Eiji Kobayashi
Tuo-Ping Li
Suzu Deguchi
Eiji Nishiyama
Hiroaki Sagawa
Ikunoshin Kato
Original Assignee
Takara Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takara Bio Inc filed Critical Takara Bio Inc
Application granted granted Critical
Publication of ATE409028T1 publication Critical patent/ATE409028T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/116—Heterocyclic compounds
    • A23K20/121—Heterocyclic compounds containing oxygen or sulfur as hetero atom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/12—Acetic acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Polymers & Plastics (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Fodder In General (AREA)
AT01946787T 2000-01-27 2001-01-26 Arzneien zur behandlung von nervenerkrankungen ATE409028T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2000019208 2000-01-27
JP2000019331 2000-01-27
JP2000254683 2000-08-24
JP2000308519 2000-10-06

Publications (1)

Publication Number Publication Date
ATE409028T1 true ATE409028T1 (de) 2008-10-15

Family

ID=27480961

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01946787T ATE409028T1 (de) 2000-01-27 2001-01-26 Arzneien zur behandlung von nervenerkrankungen

Country Status (10)

Country Link
US (1) US7268160B2 (de)
EP (1) EP1254658B1 (de)
JP (1) JP4249926B2 (de)
KR (2) KR20060095786A (de)
CN (1) CN100346776C (de)
AT (1) ATE409028T1 (de)
AU (1) AU2001228825A1 (de)
DE (1) DE60135904D1 (de)
TW (1) TWI255181B (de)
WO (1) WO2001054682A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1127572A3 (de) * 2000-02-25 2003-05-02 Basf Aktiengesellschaft Verwendung von Flavonen zur Behandlung von Cyclooxygenase-2 ermittelten Krankheiten
AU2001246877A1 (en) * 2000-04-11 2001-10-23 Takara Bio Inc. Remedies
FR2841784B1 (fr) * 2002-07-08 2007-03-02 Composition a base de derives de 1,3-diphenylprop-2en-1-one substitues, preparation et utilisations
FR2841900B1 (fr) * 2002-07-08 2007-03-02 Genfit S A Nouveaux derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations
US7361774B2 (en) 2002-10-01 2008-04-22 Takara Bio Inc. Chalcone compound
WO2004043475A1 (ja) * 2002-11-12 2004-05-27 Takara Bio Inc. 学習・記憶能力の向上剤
US20070092551A1 (en) * 2003-05-02 2007-04-26 Takara Bio Inc. Therapeutic agent
CN1890205A (zh) 2003-12-05 2007-01-03 宝生物工程株式会社 治疗剂
TW200539862A (en) * 2004-02-06 2005-12-16 Takara Bio Inc Remedy agent
JP2008542254A (ja) * 2005-05-26 2008-11-27 カウンシル オブ サイエンティフィク アンド インダストリアル リサーチ 肝細胞癌の処置に有用な医薬組成物
JP2007230946A (ja) * 2006-03-02 2007-09-13 Nagase & Co Ltd 神経突起伸長剤
JP4912708B2 (ja) * 2006-03-24 2012-04-11 三井農林株式会社 新規物質ｔｍｒ
US20100204343A1 (en) * 2007-07-25 2010-08-12 Symrise Gmbh & Co. Kg 3-(4-hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)-1-propanone and its use as antioxidant
CN102697757B (zh) * 2012-05-18 2014-06-04 广州军区广州总医院 对羟基苄叉丙酮在制备预防和/或治疗脑病药物中的应用
JP2017043572A (ja) * 2015-08-28 2017-03-02 株式会社ファンケル ヘリピロンａを有効成分とするｂｄｎｆ産生促進剤
CN109651121B (zh) * 2019-01-25 2021-11-26 陕西理工大学 一种Robtein的合成方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3761471A (en) * 1970-11-16 1973-09-25 Tamio Nishimura Benzalacetone or acetophenone amidinohydrazone derivatives and the production thereof
FI874163L (fi) 1986-09-26 1988-03-27 Mitsui Toatsu Chemicals Katekolderivat samt preparat innehaollande desamma foer haemmande och botande av regressiva sjukdomar i det centrala nervsystemet.
US5106871A (en) * 1986-12-12 1992-04-21 Tsumura & Co. Anti-ulcer agent comprising chalcone derivative as effective ingredient and novel chalcone derivative
US5234951A (en) * 1986-12-12 1993-08-10 Tsumura Juntendo, Inc. Anti-ulcer agent comprising chalcone derivative
JPS6442422A (en) 1987-08-10 1989-02-14 Tsumura & Co Antiulcer agent
JPH01125320A (ja) * 1987-11-09 1989-05-17 Tsumura & Co テストステロン−５α−リダクターゼ阻害剤
JPH02104568A (ja) 1988-06-22 1990-04-17 Yoshitomi Pharmaceut Ind Ltd 神経成長因子産生促進作用剤
JPH02187765A (ja) * 1989-01-14 1990-07-23 Oki Electric Ind Co Ltd コントラスト増強用の光脱色性層用材料およびそれを用いたパターン形成方法
JPH08768B2 (ja) * 1989-08-24 1996-01-10 武田薬品工業株式会社 神経成長因子分泌誘導剤
JPH03122645A (ja) * 1989-10-05 1991-05-24 Nippon Kanko Shikiso Kenkyusho:Kk ホトレジスト用光吸収材料
JP2719042B2 (ja) 1990-11-22 1998-02-25 三共株式会社 神経成長因子産生分泌促進剤
JPH07110812B2 (ja) 1990-12-11 1995-11-29 財団法人喫煙科学研究財団 神経成長因子生合成促進剤
JPH0578384A (ja) * 1991-03-27 1993-03-30 Taisho Pharmaceut Co Ltd フラボノール誘導体
JPH0561220A (ja) * 1991-08-30 1993-03-12 Ricoh Co Ltd 電子写真感光体
JPH05246932A (ja) * 1992-03-04 1993-09-24 Nippon High Potsukusu:Kk ３，４−ジヒドロキシカルコン誘導体
JPH07194355A (ja) * 1993-12-28 1995-08-01 Sanei Gen F F I Inc エタノール製剤
JPH07285856A (ja) * 1994-04-21 1995-10-31 Hoechst Japan Ltd 骨粗鬆症治療剤
JPH0827086A (ja) 1994-07-22 1996-01-30 Sagami Chem Res Center Ｎ−アシル−ｎ−置換シンナモイルエチレンジアミン誘導体
FR2747568B1 (fr) * 1996-04-17 1999-09-17 Oreal Utilisation d'au moins un inhibiteur de lipoxygenase et d'au moins un inhibiteur de cyclo-oxygenase pour modifier la pousse des poils et/ou des cheveux
JPH10114649A (ja) * 1996-10-15 1998-05-06 Dokutaazu Kosumeteikusu:Kk 津液改善剤及びそれを含有する経口投与用組成物
GB9712966D0 (en) 1997-06-19 1997-08-27 Indena Spa Novel chalcones
JPH11246398A (ja) * 1998-03-02 1999-09-14 Kyowa Hakko Kogyo Co Ltd 生体内過酸化脂質増加に起因する疾患の予防または治療剤
EP0998939A1 (de) * 1998-09-09 2000-05-10 The School Of Pharmacy, University Of London Chalcone Pflanzenextrakten zur Anwendung in der Therapie
WO2000048586A1 (en) * 1999-02-19 2000-08-24 Takara Shuzo Co., Ltd. Remedies
WO2000062785A1 (en) 1999-04-15 2000-10-26 Takara Shuzo Co., Ltd. Remedies
WO2001030335A2 (en) * 1999-10-22 2001-05-03 The Board Of Trustees Of The University Of Illinois Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease

Also Published As

Publication number Publication date
AU2001228825A1 (en) 2001-08-07
KR20060095786A (ko) 2006-09-01
EP1254658A4 (de) 2003-06-18
DE60135904D1 (de) 2008-11-06
JP4249926B2 (ja) 2009-04-08
EP1254658A1 (de) 2002-11-06
CN1419448A (zh) 2003-05-21
WO2001054682A1 (en) 2001-08-02
KR100711537B1 (ko) 2007-04-27
TWI255181B (en) 2006-05-21
EP1254658B1 (de) 2008-09-24
US7268160B2 (en) 2007-09-11
KR20020073186A (ko) 2002-09-19
CN100346776C (zh) 2007-11-07
US20030144316A1 (en) 2003-07-31

Similar Documents

Publication Publication Date Title
ATE409028T1 (de) Arzneien zur behandlung von nervenerkrankungen
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
ATE405564T1 (de) 1h-imidazoä4,5-cüchinolinderivate zur behandlung von protein kinase-abhängigen krankheiten
DE60126829D1 (de) Kombination von drei Substanzen zur Vorbeugung und Behandlung von Arthritis
AU2001272735A1 (en) Novel physiologically active peptide and use thereof
ATE388951T1 (de) Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
EA200100524A1 (ru) Амиды антраниловой кислоты и их применение в качестве лекарственных средств
WO2003099771A3 (en) Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
MXPA05006940A (es) Formulaciones terapeuticas para el tratamiento de enfermedades relacionadas con beta - amiloide.
ATE412646T1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
DE69521536D1 (de) Zusammensetzungen die G-CSF und ein TNF-Bindungsprotein enthalten
DE60233433D1 (de) PHARMAZEUTISCHE ZUBEREITUNG enthaltend ein Catechin, Ascorbinsäure, Prolin und Lysin ZUR BEHANDLUNG VON NEOPLASTISCHEN KRANKHEITEN
ATE367387T1 (de) Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden
AU2001266289A1 (en) 2-arachidonylglycerol (2-ag) - an inhibitor of tumor necrosis factor -alfa and neuroprotector of brain in closed head injury
ATE265851T1 (de) Behandlung von erkrankungen, die vom cytokinwachstumsfaktor verursacht werden
ATE192923T1 (de) Verwendung von boswelliasäure zur behandlung von hirntumoren
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.
ATE285773T1 (de) Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten
CA2429793A1 (en) Interferon therapeutic effect enhancer
ATE548048T1 (de) Oncomodulin zur behandlung von neurologishen erkrankungen
DE60306503D1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
DE68916651D1 (de) Heilmittel zur behandlung von toxoplasmose.
DE69428797D1 (de) Verwendung von benzydamin zur behandlung von krankheitszuständen, die durch tnf verursacht werden
ATE350034T1 (de) Verwendung von epothilone zur behandlung hyperparathyreoidismus
DE60108775T8 (de) Methode zur behandlung von schlaganfall

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties